As we observed significantly improved expansion and long-term persistence of ITK-deficient CD19-CAR-T cells compared with nt-KO CD19-CAR-T cells in vivo, we speculated that mice receiving ITK-KO CD19-CAR-T cells might be better protected against tumor relapse. This evidence concerns the gene CD19 and neoplasm.